AACR 2016


© AACR/Todd Buchanan

Session at the 2016 AACR Annual Meeting, which took place April 16-20 in New Orleans, Louisiana.


Change in T-cell distribution predicts LFS, OS in AML

HT Staff Read Article
Published: 04/21/16

AML cells

A phase 4 study has revealed biomarkers that appear to predict the efficacy of treatment with histamine dihydrochloride (HDC) and interleukin-2 (IL-2) in patients with acute myeloid leukemia (AML). Researchers found that patients who remained in complete remission after 1 cycle of HDC/IL-2 experienced a significant reduction in effector memory T cells (TEM) and a concomitant increase in effector T cells (Teff) during therapy. [Read Article]

Treatment can produce durable responses in NHL

HT Staff Read Article
Published: 04/20/16

Attendees in session at
2016 AACR Annual Meeting
© AACR/Todd Buchanan

Administering an antibody-radionuclide conjugate after B-cell depletion with rituximab can produce lasting responses in patients with relapsed non-Hodgkin lymphoma (NHL), according to a phase 1/2 study. The conjugate, 177Lu-DOTA-HH1 (Betalutin), consists of the tumor-specific antibody HH1, which targets the CD37 antigen on the surface of NHL cells, conjugated to the β-emitting isotope lutetium-177 (Lu-177) via the chemical linker DOTA. [Read Article]

Drug shows early promise for low-grade lymphoma

HT Staff Read Article
Published: 04/20/16

Micrograph showing
follicular lymphoma

The TLR9 agonist SD-101 has produced encouraging early results in patients with low-grade B-cell lymphoma, according to researchers. In an ongoing phase 1/2 study, patients received low-dose radiation, followed by an injection of SD-101 into one of their tumors. This prompted changes in the tumor microenvironment that potentially induced a systemic antitumor response and decreased the volume of both treated and untreated tumors.  [Read Article]

mAb can reduce CSCs in newly diagnosed MM

HT Staff Read Article
Published: 04/19/16

Monoclonal antibodies
Photo by Linda Bartlett

A small study suggests that treatment with lenalidomide and dexamethasone (len-dex) prompts an increase in cancer stem cells (CSCs) for patients with newly diagnosed multiple myeloma (MM). However, adding an anti-CD19 monoclonal antibody (mAb) to the regimen can reduce CSCs. Most patients who received the mAb, MEDI-551, experienced a decrease in CSCs, but the cells rebounded after the patients stopped receiving MEDI-551. [Read Article]

Antibody shows activity against ALL, CLL

HT Staff Read Article
Published: 04/19/16

Lab mice
Photo by Aaron Logan

Preclinical data suggest IMMU-114, a humanized anti-HLA-DR IgG4 antibody, is active against acute and chronic leukemias. In a mouse model of chronic lymphocytic leukemia (CLL), IMMU-114 significantly prolonged survival when compared to rituximab. IMMU-114 also produced a significant survival benefit in a mouse model of acute lymphoblastic leukemia (ALL) that is refractory to doxorubicin. [Read Article]


    {icon} {author} Read Article
    Published: {pubDate}